Chikungunya vaccine shows promise in Long-Term antibody persistence study

NCT ID NCT04838444

First seen Dec 24, 2025 · Last updated May 14, 2026 · Updated 20 times

Summary

This study looks at how long the chikungunya vaccine (VLA1553) keeps working and if it stays safe over time. About 363 adults who got the vaccine in an earlier trial are being followed. Researchers measure antibody levels and watch for any serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Accelerated Enrollment Solutions (AES)

    Phoenix, Arizona, 85020, United States

  • Accelerated Enrollment Solutions (AES)

    Chicago, Illinois, 60602, United States

  • Alliance for Multispecialty Research (AMR)

    Lexington, Kentucky, 40509, United States

  • Alliance for Multispecialty Research (AMR)

    Knoxville, Tennessee, 37920, United States

  • Allliance for Multispecialty Research (AMR)

    Norfolk, Virginia, 23502, United States

  • Velocity Clinical Research

    Hallandale, Florida, 33090, United States

  • Velocity Clinical Research

    Grand Island, Nebraska, 68803, United States

  • Velocity Clinical Research

    Omaha, Nebraska, 68134, United States

  • Velocity Clinical Research

    Austin, Texas, 78759, United States

  • Velocity Clinical Research

    West Jordan, Utah, 84088, United States

Conditions

Explore the condition pages connected to this study.